Clinical Trial: Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

Brief Summary: Canavan disease is caused by Aspartoacylase deficiency. There is no treatment for the disease, but there is a food additive that includes acetate . We suggest an early treatment with acetate and a neurologic evaluation, including MRI, after 4 months of treatment. In any case the treatment will be stopped at the age of 22 months, when myelinization is ended.

Detailed Summary:
Sponsor: Shaare Zedek Medical Center

Current Primary Outcome: brain MRI at the end of the study [ Time Frame: 6 months ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Shaare Zedek Medical Center

Dates:
Date Received: June 18, 2008
Date Started: March 2008
Date Completion:
Last Updated: June 20, 2011
Last Verified: June 2011